Stmnt re Share Price Movement

Ultrasis plc

("Ultrasis" or the "Company")

Announcement regarding share price movement

The Company notes the recent share price movement. The Board confirms that it remains in discussions with Paul Bell with regards the ongoing financing of the Company.

The Board is hopeful that Mr Bell may agree to lead a refinancing through a mixture of debt and equity. Any equity element is likely to be issued at a price of 0.05 pence per ordinary share, a substantial discount to the current share price. Current proposals being discussed would enable existing shareholders to participate in any equity offering alongside, and on the same terms, as Mr Bell.

Any refinancing would be subject to a number of a number of conditions, inter alia:

- the satisfactory conclusion of a limited due diligence exercise to be conducted by Mr Bell and/or other advisors appointed by Mr Bell for this purpose; and

- the approval of a waiver under Rule 9 of the Takeover Code as any significant equity investment would result in Mr Bell owning more than 30% of the voting rights in the Company

Discussions remain ongoing and there can be absolutely no certainty that an agreement can be reached.

For all enquiries relating to Ultrasis please contact:

Notes to Editors:

Ultrasis is a healthcare company with core expertise in health, psychology, software development and programme management. We deliver a range of healthcare products to the consumer, the NHS, the corporate sector and other healthcare providers in the UK and Internationally. Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is still the world leader in this field.